Chronic Thrombocytopenia Workup

Essential Initial Evaluation

• The American Society of Hematology recommends that the workup for chronic thrombocytopenia begins with history, physical examination, complete blood count, and peripheral blood smear evaluation by a qualified hematologist or pathologist, which is sufficient for most patients under 60 years without atypical features 1, 2
• A medication review is necessary to document all current and recent medications, particularly heparin, quinidine/quinine, sulfonamides, and alcohol use, as these commonly cause thrombocytopenia 2, 3
• Assessing bleeding history, including mucocutaneous bleeding, prior surgeries, and pregnancies, is crucial to gauge hemostatic function 3
• Identifying infection risk factors, such as HIV risk factors, recent viral illnesses, and immunization history, is essential 1, 2
• Screening for systemic symptoms, such as fever, weight loss, night sweats, arthralgias, or rash, can help identify autoimmune disease or lymphoproliferative disorders 1, 4
• Obtaining a family history of inherited thrombocytopenias, including Wiskott-Aldrich syndrome, MYH9-related disease, and Bernard-Soulier syndrome, is vital 1
• Recent transfusions should be noted, as they raise the possibility of posttransfusion purpura 1

Physical Examination

• The physical examination should be normal aside from petechiae, purpura, or ecchymosis, with mild splenomegaly possibly occurring in younger patients 1, 4
• Moderate or massive splenomegaly indicates an alternative diagnosis, such as lymphoproliferative disease or portal hypertension 1, 4
• Lymphadenopathy or hepatomegaly suggests underlying HIV, systemic lupus erythematosus, or lymphoproliferative disease rather than primary immune thrombocytopenia 1, 4

Laboratory Studies

• Isolated thrombocytopenia is characterized by a normal complete blood count (CBC) with otherwise normal results, and anemia should be proportional to bleeding duration 1, 4
• A normal white blood cell count and morphology are expected, with abnormalities suggesting an alternative diagnosis 1, 4
• Platelet morphology should be normal or slightly larger than normal, with consistently giant platelets indicating inherited thrombocytopenia 1, 5
• EDTA-dependent platelet agglutination must be ruled out by examining the smear or repeating the count in a citrate or heparin tube 1, 4
• Red blood cell morphology, including schistocytes, can indicate thrombotic thrombocytopenic purpura-hemolytic uremic syndrome rather than immune thrombocytopenic purpura (ITP) 1, 4
• Leukocyte inclusions, such as Döhle-like bodies, may suggest MYH9-related disease 1, 4

Mandatory Serologic Testing in Adults

• All adult patients with suspected chronic thrombocytopenia require HIV and hepatitis C virus testing, regardless of risk factors or geographic location 1, 4
• HIV testing is crucial, as thrombocytopenia may precede other HIV symptoms by years, and controlling the infection can result in complete hematologic remission 1, 4
• Hepatitis C virus testing is necessary, as HCV-associated thrombocytopenia is clinically indistinguishable from primary ITP 1, 4
• Helicobacter pylori testing should be considered in adults where eradication may have a clinical impact 1, 4

Bone Marrow Examination: When Required

• Bone marrow examination is indicated in patients older than 60 years, those with systemic symptoms or abnormal physical findings, or when splenectomy is considered 1, 4
• Age greater than 60 years is a mandatory indication for bone marrow examination to exclude myelodysplastic syndromes, leukemias, or other malignancies 1, 4
• Systemic symptoms, such as fever, weight loss, bone pain, or constitutional symptoms, require bone marrow examination 1, 4
• Abnormal blood counts, including anemia not proportional to bleeding, leukopenia, or leukocytosis, necessitate bone marrow examination 1, 4
• Atypical smear findings, such as schistocytes, leukocyte inclusion bodies, or dysplastic features, require bone marrow examination 1, 4
• Treatment failure, defined as persistent thrombocytopenia lasting more than 6-12 months or unresponsive to IVIg, necessitates bone marrow examination 2, 6
• Pre-splenectomy evaluation should consider bone marrow examination in some cases 1, 4

Bone Marrow Testing Components

• Morphologic assessment, including both aspirate and biopsy, is required for bone marrow examination 1, 4
• Flow cytometry is particularly helpful for identifying chronic lymphocytic leukemia-associated ITP 1, 4
• Cytogenetic testing should be considered to exclude clonal disorders 1, 4

Additional Testing Based on Clinical Context

• Quantitative immunoglobulin levels should be considered in children with ITP, especially those with persistent or chronic disease, to exclude common variable immunodeficiency 1, 7
• Direct antiglobulin test may be useful in selected cases 1, 7
• Blood group Rh(D) typing is important if anti-D immunoglobulin therapy is being considered 1, 4
• Pregnancy test should be performed in women of childbearing potential 7

Algorithmic Approach to Chronic Thrombocytopenia Workup

• Step 1: Confirm true thrombocytopenia by repeating the CBC in a citrate or heparin tube and reviewing the peripheral blood smear by a qualified hematologist or pathologist 1, 4
• Step 2: Determine if isolated thrombocytopenia is present; if isolated, proceed with ITP workup, and if not isolated, consider bone marrow examination and broader differential diagnosis 1, 4
• Step 3: Age-based stratification is necessary, with patients under 60 years with typical features requiring history, physical, CBC, smear, HIV, HCV, and H. pylori testing, while bone marrow examination is mandatory for patients 60 years or older 1, 2, 4
• Step 4: Assess for atypical features, such as splenomegaly, lymphadenopathy, systemic symptoms, or abnormal smear; if any atypical features are present, proceed to bone marrow examination 1, 4

#

Evidence‑Based Diagnostic Work‑Up for Thrombocytopenia

Peripheral Blood Smear Review

• Manual review of a peripheral blood smear by a qualified hematopathologist is essential because automated counters can miss platelet clumping, giant platelets, and schistocytes, which are critical for distinguishing true thrombocytopenia from pseudothrombocytopenia or inherited disorders. 8
• The presence of giant platelets that approach red‑cell size on smear suggests inherited thrombocytopenias such as MYH9‑related disease or Bernard‑Soulier syndrome. 8
• Leukocyte inclusion bodies (e.g., Döhle‑like inclusions) on the smear are a clue toward MYH9‑related disease. 8
• Abnormal white‑cell morphology (immature cells, blasts) or additional cytopenias on the smear indicate the need to evaluate for leukemia or myelodysplastic syndrome. 8

Clinical Assessment (History & Physical)

• A normal physical examination limited to bleeding signs (petechiae, purpura, ecchymoses) supports a diagnosis of primary immune thrombocytopenia (ITP). 9
• Moderate or massive splenomegaly, hepatomegaly, or lymphadenopathy excludes primary ITP and mandates targeted investigations for HIV, systemic lupus erythematosus, lymphoproliferative disorders, or portal hypertension. 9
• Constitutional “B‑symptoms” (fever, unexplained weight loss, night sweats, bone pain) or syndromic features (e.g., hearing loss, skeletal dysmorphisms) require immediate bone‑marrow examination. 9

Routine Laboratory Evaluation

• Isolated thrombocytopenia (platelet count < 100 × 10⁹/L) with otherwise normal complete blood count is the typical laboratory pattern of primary ITP. 9
• HIV antibody testing is required in every adult with suspected ITP, because HIV‑associated thrombocytopenia can be clinically indistinguishable from primary ITP. 9
• Hepatitis C virus serology is mandatory in all adults with suspected ITP, as chronic HCV can cause secondary thrombocytopenia that resolves with antiviral therapy. 9
• Helicobacter pylori testing (urea‑breath test or stool antigen) should be performed in adults, since eradication normalizes platelet counts in a subset of patients, especially in high‑prevalence regions. 9
• Coagulation studies (PT, aPTT, fibrinogen, D‑dimer) are recommended in patients with severe thrombocytopenia to assess for disseminated intravascular coagulation. 10

Indications for Bone‑Marrow Examination

• Age ≥ 60 years – mandatory bone‑marrow aspirate and core biopsy to exclude myelodysplastic syndrome, leukemia, or other clonal disorders. 9
• Presence of any additional cytopenia beyond isolated thrombocytopenia (e.g., anemia or leukopenia) – bone‑marrow evaluation required. 9
• Abnormal peripheral‑smear findings (schistocytes, giant platelets, leukocyte inclusion bodies, immature white cells) – bone‑marrow assessment indicated. 9
• Pre‑splenectomy evaluation in chronic ITP patients – bone‑marrow examination recommended. 9
• Conversely, patients < 60 years with typical ITP features (isolated thrombocytopenia, normal exam, normal smear, no systemic symptoms) do not require bone‑marrow testing. 9
• Children and adolescents with classic ITP presentation (recent viral prodrome, skin‑only bleeding, normal exam) also do not need bone‑marrow examination. 9

Special Populations

• In children with typical ITP, observation alone is appropriate regardless of platelet count; 60‑74 % achieve spontaneous remission within six months. 9
• Pregnancy testing in women of child‑bearing potential is essential to differentiate gestational thrombocytopenia, pre‑eclampsia, or HELLP syndrome from ITP. 9
• Rh(D) blood‑group typing is required before considering anti‑D immunoglobulin therapy. 9
• Quantitative immunoglobulin measurement in children with persistent or chronic ITP helps exclude common variable immunodeficiency. 9

Heparin‑Induced Thrombocytopenia (HIT)

• The 4T score should be calculated in any patient who received heparin (including flushes) within the preceding three months. 10
• If the 4T score is ≥ 4 (intermediate/high probability), all heparin must be stopped immediately and anti‑PF4 antibody testing ordered without awaiting results. 10
• Non‑heparin anticoagulants (e.g., argatroban, bivalirudin, fondaparinux) should be initiated promptly; treatment must not be delayed for laboratory confirmation. 10
• HIT typically manifests 5‑10 days after heparin exposure with a moderate platelet drop (30‑70 × 10⁹/L) and a paradoxical risk of thrombosis rather than bleeding. 10

Medication‑Related Thrombocytopenia

• Common drug culprits include heparin, quinidine/quinine, sulfonamides, vancomycin, cefazolin, clindamycin, doxycycline, trimethoprim‑sulfamethoxazole, GPIIb/IIIa inhibitors, and alcohol. A thorough medication review is mandatory. 8
• Drug‑induced thrombocytopenia usually appears 5‑14 days after exposure to the offending agent.

Tests Not Recommended for Routine Use

• Platelet‑associated IgG and glycoprotein‑specific antiplatelet antibody assays lack diagnostic specificity and do not influence management decisions. 8
• Thrombopoietin level measurement, immature platelet fraction, bleeding time, and routine antiphospholipid antibody testing (absent clinical suspicion) are not recommended.

All statements are supported by the cited peer‑reviewed sources.